MARKET

ENLV

ENLV

Enlivex Therapeutics Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.65
+0.65
+5.91%
After Hours: 11.34 -0.31 -2.66% 18:58 09/17 EDT
OPEN
10.88
PREV CLOSE
11.00
HIGH
11.77
LOW
10.71
VOLUME
88.78K
TURNOVER
--
52 WEEK HIGH
29.40
52 WEEK LOW
4.730
MARKET CAP
213.27M
P/E (TTM)
-12.5269
1D
5D
1M
3M
1Y
5Y
Enlivex to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Nes-Ziona, Israel, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors...
GlobeNewswire · 09/09 12:00
Here's Why Enlivex Therapeutics Ltd. (ENLV) is a Great Momentum Stock to Buy
Zacks.com · 09/03 16:00
US Indexes End With More Record Highs Monday
GuruFocus News · 08/16 20:49
Mid-Afternoon Market Update: Dow Turns Positive; Sesen Bio Shares Plummet
Toward the end of trading Monday, the Dow traded up 0.03% to 35,526.99 while the NASDAQ fell 0.34% to 14,771.91. The S&P also rose, gaining 0.02% to 4,468.88.
Benzinga · 08/16 18:32
ASRT, GOCO, AEYE among mid-day movers
Gainers: NanoVibronix (NASDAQ:NAOV) +47%. Enlivex Therapeutics (NASDAQ:ENLV) +20%. GoHealth (NASDAQ:GOCO) +16%. Travere Therapeutics (NASDAQ:TVTX) +16%. Collegium Pharmaceutical (NASDAQ:COLL) +16%. Auddia (NASDAQ:AUUD) +15%. AudioEye (NASDAQ:AEYE) +14%. Co...
Seekingalpha · 08/16 16:38
38 Stocks Moving In Monday's Mid-Day Session
Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares climbed 34.5% to $3.3900 after the company announced plan to expand product portfolio with introduction of Painshield relief for over-the-counter use and plans for future product launch.
Benzinga · 08/16 16:03
NanoVibronix, Nymox Pharmaceutical leads healthcare gainers; Sesen Bio, ESSA Pharma among major losers
Gainers: NanoVibronix NAOV +44%, Nymox Pharmaceutical (NASDAQ:NYMX) +21%, Travere Therapeutics TVTX +20%, Enlivex Therapeutics ENLV +15%, Collegium Pharmaceutical COLL +11%. Losers: Sesen Bio SESN -35%, ESSA Pharma EPIX -32%, Absci (NASDAQ:ABSI) -17%, Clev...
Seekingalpha · 08/16 15:01
Sector Update: Health Care
MT Newswires · 08/16 13:25
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ENLV. Analyze the recent business situations of Enlivex Therapeutics Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ENLV stock price target is 33.00 with a high estimate of 33.00 and a low estimate of 33.00.
EPS
Institutional Holdings
Institutions: 25
Institutional Holdings: 987.57K
% Owned: 5.39%
Shares Outstanding: 18.31M
TypeInstitutionsShares
Increased
5
42.67K
New
4
93.58K
Decreased
6
149.29K
Sold Out
7
58.80K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chief Executive Officer
Oren Hershkovitz
Vice Chairman/Executive Director/Director
Shai Novik
Founder/Chief Scientific Officer
Dror Mevorach
Chief Financial Officer
Shachar Shlosberger
Director
Baruch Halpert
Director
Bernhard Kirschbaum
Director
Sangwoo Lee
Director
Brian Schwartz
Independent Director
Michel Habib
Independent Director
Gili Hart
Independent Director
Abraham Havron
No Data
  • All
  • Financials
  • Insiders
More
About ENLV
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

Webull offers kinds of Enlivex Therapeutics Ltd stock information, including NASDAQ:ENLV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENLV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ENLV stock methods without spending real money on the virtual paper trading platform.